Advertisement

Intravesical Therapy

Chapter

Abstract

Instillation therapy remains an important therapeutic approach to bladder pain syndrome (BPS) for ameliorating or delaying recurrence of symptoms. Instillations of drugs into the bladder create a high concentration of drugs locally at the disease site without increasing systemic levels, which can explain the low risk of systemic side effects.

A large body of evidence supports the notion that symptoms of BPS emanate from underlying inflammation in the bladder. The intravesical route offers reasonable adjunctive therapies for immediate symptom relief during symptom flare-up. Disadvantages include the need for intermittent catheterization, which can be painful in BPS patients, the cost, and the general risk of iatrogenic infection.

Keywords

Hyaluronic Acid International Prostate Symptom Score Urothelial Cell Intravesical Instillation Bladder Pain Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Peeker R, Haghsheno MA, Holmang S, Fall M. Intravesical bacillus Calmette-Guerin and dimethyl sulfoxide for treatment of classic and nonulcer BPS: a prospective, randomized double-blind study. J Urol. 2000;164:1912.PubMedCrossRefGoogle Scholar
  2. 2.
    Perez-Marrero R, Emerson LE, Feltis JT. A controlled study of dimethyl sulfoxide in BPS. J Urol. 1988;140:36.PubMedGoogle Scholar
  3. 3.
    Sant GR. Intravesical 50% dimethyl sulfoxide (Rimso-50) in treatment of BPS. Urology. 1987;29:17.PubMedGoogle Scholar
  4. 4.
    Rossberger J, Fall M, Peeker R. Critical appraisal of dimethyl sulfoxide treatment for BPS: discomfort, side-effects and treatment outcome. Scand J Urol Nephrol. 2005;39:73.PubMedCrossRefGoogle Scholar
  5. 5.
    Hanno P. BPS and related disorders. In: Walsh PC, editor. Campbell’s urology. Philadelphia: Elsevier; 2002. p. 631–68.Google Scholar
  6. 6.
    Szallasi A, Blumberg PM. Resiniferatoxin, a phorbol-related diterpene, acts as an ultrapotent analog of capsaicin, the irritant constituent in red pepper. Neuroscience. 1989;30:515–20.PubMedCrossRefGoogle Scholar
  7. 7.
    Szallasi A, Blumberg PM. Resiniferatoxin and its analogs provide novel insights into the pharmacology of the vanilloid (capsaicin) receptor. Life Sci. 1990;47:1399–408.PubMedCrossRefGoogle Scholar
  8. 8.
    Avelino A, Cruz F. TRPV 1 (vanilloid receptors) in the urinary tract: expression, function and clinical applications. Naunyn Schmiedebergs Arch Pharmacol. 2006;373:289–99.CrossRefGoogle Scholar
  9. 9.
    Silva C, Rio ME, Criz F. Desensitization of bladder sensory fibers by intravesical resiniferatoxin, a capsaicin analog: long-term results for the treatment of detrusor hyeprreflexia. Eur Urol. 2000;38:444–52.PubMedCrossRefGoogle Scholar
  10. 10.
    Silva C, Ribeiro MJ, Cruz F. The effect of intrevesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contraction are triggered by C-fiber input. J Urol. 2002;168:575–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Mourtoukou EG, Iavazzo C, Falagas ME. Resiniferatoxin in the treatment of BPS: a systematic review. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19:1571–6.CrossRefGoogle Scholar
  12. 12.
    Payne CK, Mosbaugh PG, Forrest JB, et al. Intravesical resiniferatoxin for the treatment of BPS: a randomized, double blind, placebo controlled trial. J Urol. 2005;173:1590–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Lazzeri M, Beneforti P, Spinelli M, Zanollo A, Barbagli F, Turini D. Intravesical resiniferatoxin for the treatment of hypersensitive disorder: a randomized placebo controlled study. J Urol. 2000;164:676–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Chen TY, Corcos J, Camel M, et al. Prospective, randomized, double-blind study of safety and tolerability of intravesical resiniferatoxin (RTX) in BPS (IC). Int Urogynecol J Pelvic Floor Dysfunct. 2005;16:293–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Apostolidis A, Gonzales GE, Fowler CJ. Effect of intravesical resiniferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters, and quality of life of patients with urodynamic increased bladder sensation. Eur Urol. 2006;50:1299–305.PubMedCrossRefGoogle Scholar
  16. 16.
    Peng CH, Kuo HC. Multiple intravesical instillationof low-dose resiniferatoxin in the treatment of refractory BPS. J Urol. 2007;78:78–81.Google Scholar
  17. 17.
    Lazzeri M, Spinelli M, Beneforti P, et al. Intravesical infusion of resiniferatoxin by a temporary in situ drug delivery system to treat interstitiasl cystitis. Eur Urol. 2000;164:676–9.Google Scholar
  18. 18.
    Hurst RE. Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract. World J Urol. 1994;12:3–10.PubMedCrossRefGoogle Scholar
  19. 19.
    Toft BR, Nordling J. Recent developments of intravesical therapy of painful bladder syndrome/BPS: a review. Curr Opin Urol. 2006;16:268–72.PubMedCrossRefGoogle Scholar
  20. 20.
    Bade JJ, Laseur M, Nieuwenburg A, et al. A placebo controlled study of intravesical pentosanpolysulphate for the treatment of BPS. Br J Urol. 1997;79:168–71.PubMedCrossRefGoogle Scholar
  21. 21.
    Daha LK, Lazar D, Simak R, Pfuger H. The effects of intravesical pentosanpolysulphate treatment on the symptoms of patients with bladder pain syndrome/BPS: preliminary results. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19:987–90.PubMedCrossRefGoogle Scholar
  22. 22.
    Davis EL, El Khoundary SR, Talbott EO, et al. Safety and efficacy of the use of intravesical and oral pentosan polysulphate sodium for BPS: a randomized double-blind clinical trial. J Urol. 2008;179:177–85.PubMedCrossRefGoogle Scholar
  23. 23.
    Kuo HC. Urodynamic results of intravesical heparin therapy for women with frequency urgency syndrome and BPS. J Formos Med Assoc. 2001;100:309.PubMedGoogle Scholar
  24. 24.
    Parsons CL, Housley T, Schmidt JD, Lebow D. Treatment of BPS with intravesical heparin. Br J Urol. 1994;73:504.PubMedCrossRefGoogle Scholar
  25. 25.
    Perez-Marrero R, Emerson LE, Maharajh DO, et al. Prolongation of response to DMSO by heparin maintenance. Urology. 1993;41(Suppl):64.PubMedCrossRefGoogle Scholar
  26. 26.
    Parsons CL. Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with BPS. Urology. 2005;65:45.PubMedCrossRefGoogle Scholar
  27. 27.
    Welk BK, Teichman JM. Dyspareunia response in patients with BPS treated with intravesical lidocaine, bicarbonate, and heparin. Urology. 2008;71:67–70.PubMedCrossRefGoogle Scholar
  28. 28.
    Morales A, Emerson L, Nickel JC. Intravesical hyaluronic acid in the treatment of refractory BPS. J Urol. 1996;156:45–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Porru D, Campus G, Tudino D, Valdes E, Vespa A, Scarpa RM, Usai E. Results of treatment of refractory BPS with intravesical hyaluronic acid. Urol Int. 1997;59(1):26–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Kallenstrup EB, Joregensen S, Nordling J, Hald T. Treatment of BPS with Cystistat®: a hyaluronic acid product. Scand J Urol Nephrol. 2005;39:143–7.CrossRefGoogle Scholar
  31. 31.
    Daha LK, Riedl CR, Lazar D, Hohlbrugger G, Pfluger H. Do cystometric findings predict the results of intravesical hyaluronic acid in women with BPS? Eur Urol. 2005;47:393–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Leppilahti M, Hellstrom P, Tammela TL. Effect of diagnostic hydrodistension and four intravesical hyaluronic acid instillations on bladder ICAM-1 intensity and association of ICAM-1 intensity with clinical response in patients with interstitialcystitis. Urology. 2002;60(1):46–51.PubMedCrossRefGoogle Scholar
  33. 33.
    Ahmad I, Sarath Krishna N, Meddings RM. Sequential hydrodistension and intravesical instillation of hyaluronic acid under general anaesthesia for treatment of refractory BPS: a pilot study. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19:543–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Steinhoff G, Ittah B, Rowan S. The efficacy of chondroitin sulfate 0.2% in treating BPS. Can J Urol. 2002;9(1):1454–8.PubMedGoogle Scholar
  35. 35.
    Nickel JC, Egerdie B, Downey J, Singh R, Skehan A, Carr L, Irvine-Bird K. A real-life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of BPS. BJU Int. 2009;103(1):56–60. Epub 2008 Sep 3.PubMedCrossRefGoogle Scholar
  36. 36.
    Nickel JC, Egerdie RB, Steinhoff G, Palmer B, Hanno P. A multicenter, randomized, double-blind, parallel group pilot evaluation of the efficacy and safety of intravesical sodium chondroitin sulfate versus vehicle control in patients with BPS/painful bladder syndrome. Urology. 2010;76:804–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Cervigni M, Natale F, Nasta L, Padoa A. A combined intravesical therapy with hyaluronic acid and chondroitin for refractory painful bladder syndrome/BPS. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19:943–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Porru D, Cervigni M, et al. Results of endovesical hyaluronic acid/chondroitin sulfate in the treatment of BPS/painful bladder syndrome. Rev Recent Clin Trials. 2008;3:126–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Peters K, Diokno A, Steinert B, et al. The efficacy on intravesical Tice strain bacillus Calmette-Guerin in the treatment of BPS: a double-blind, prospective, placebo controlled trial. J Urol. 1997;157:2090–4.PubMedCrossRefGoogle Scholar
  40. 40.
    Peters KM, Diokno AC, Steinert BW, Gonzalez JA. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of BPS: long-term followup. J Urol. 1998;159:1483.PubMedCrossRefGoogle Scholar
  41. 41.
    Mayer R, Propert KJ, Peters KM, et al. A randomized controlled trial of intravesical bacillus calmette-guerin for treatment of refractory BPS. J Urol. 2005;173:1186–91.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of UrogynecologyS. Carlo-IDI, Catholic UniversityRomeItaly
  2. 2.Department Obstetrics and GynecologyCatholic UniversityRomeItaly
  3. 3.Division of Neuro-Urology, Marienhospital HerneUniversity Hospital of BochumHerneGermany

Personalised recommendations